ESL Tutti-Frutti taste — Competitive Intelligence Brief

ESL Tutti-Frutti taste (ESL Tutti-Frutti taste) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor. Area: Diabetes.

phase 2 DPP-4 inhibitor DPP-4 Diabetes Small molecule

Target snapshot

ESL Tutti-Frutti taste (ESL Tutti-Frutti taste) — Bial - Portela C S.A.. ESL works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4).

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ESL Tutti-Frutti taste TARGET	ESL Tutti-Frutti taste	Bial - Portela C S.A.	phase 2	DPP-4 inhibitor	DPP-4
Sitagliptin combined with metformin	Sitagliptin combined with metformin	Sun Yat-sen University	marketed	DPP-4 inhibitor combined with biguanide	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I
Sitagliptin (Januvia)	Sitagliptin (Januvia)	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	marketed	DPP-4 inhibitor	DPP-4 (dipeptidyl peptidase-4)
Saxagliptin + Metformin	Saxagliptin + Metformin	AstraZeneca	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I and AMPK
Incretin-based therapy	Incretin-based therapy	Nagaoka Red Cross Hospital	marketed	Incretin mimetic or DPP-4 inhibitor	GLP-1 receptor or DPP-4
Pioglitazone + Alogliptin	Pioglitazone + Alogliptin	Celltrion Pharm, Inc.	marketed	Thiazolidinedione + DPP-4 inhibitor combination	PPAR-γ and DPP-4
Sitagliptin + Metformin	Sitagliptin + Metformin	Baylor College of Medicine	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor class)

1. Merck Sharp & Dohme LLC · 5 drugs in this class
2. Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
3. AstraZeneca · 4 drugs in this class
4. LG Life Sciences · 2 drugs in this class
5. Tanabe Pharma Corporation · 2 drugs in this class
6. Ain Shams University · 2 drugs in this class
7. Ono Pharmaceutical Co. Ltd · 2 drugs in this class
8. Cinnagen · 1 drug in this class
9. GRADE Study Group · 1 drug in this class
10. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class